Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Reports Third Quarter 2025 Financial Results and Revises Full Year Guidance
Summary
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the third quarter of 2025, showing total revenue of $3.08 billion, an 11% increase year-over-year. The company also refined its full-year financial guidance, expecting total revenue between $11.9 and $12.0 billion, with combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expenses anticipated to be between $5.65 and $5.8 billion and $5.0 to $5.1 billion, respectively. Vertex also lowered its non-GAAP effective tax rate guidance for 2025 to a range of 17% to 18%. The press release included details on the performance of its marketed products, progress in its R&D pipeline, and non-GAAP financial measures.
Profitelligence Alerts
Get alerts for VRTX
Be first to know when Vertex Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.
Official SEC Documents
Advertisement